课题基金 / 基金详情

GOG 163:STUDY OF DOXORUBICIN+CISPLATIN VS DOXORUBICIN+24 HOUR PACLITA

GOG 163:STUDY OF DOXORUBICIN+CISPLATIN VS DOXORUBICIN+24 HOUR PACLITA
GOG 163:阿霉素顺铂与阿霉素 24 小时 PACLITA 的研究
批准号:
6265789
负责人:
WILLIAM R ROBINSON
金额:
$1.12万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-19 至 1999-11-30

项目摘要

项目成果

WILLIAM R ROBINSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
There is no standard treatment for advanced endometrial cancer. Once the tumor has spread beyond the uterus, treatment with surgery ad pelvic radiation may not be sufficient to control the disease and additional therapy may be helpful. In a previous GOG (Gynecologic Oncology Group) study the chemotherapy agents, doxorubicin and cisplatin, have been given to patients with advanced endometrial cancer and over 40% of patients had a response to this combination of drugs. Another chemotherapy agent, paclitaxel, has been shown to reduce the tumor size in some patients with endometrial cancer. The purpose of this study is to determine whether treatment with paclitaxel and doxorubicin is more effective than treatment with doxorubicin and cisplatin in patients with primary Stage III and IV or recurrent endometrial cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cytotoxic T Lymphocyte Immunotherapy for Ovarian Cancer
Cytotoxic T Lymphocyte Immunotherapy for Ovarian Cancer
SWOG 9717:EVALUATION OF INTRAVENOUSLY ADMINISTERED TIRAPAZAMINE + CIS
  • 批准号:
    6265795
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    WILLIAM R ROBINSON
  • 依托单位:
GOG 172:IV PACLITAXEL & CISPLATIN VS IV PACLITAXEL IN EPITHELIAL OVAR
  • 批准号:
    6265786
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    WILLIAM R ROBINSON
  • 依托单位:
海外基金